

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Clinical Care of Patients with Urothelial Bladder Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following outcomes was reported with erdafitinib compared to chemotherapy for patients with previously treated FGFR-altered metastatic urothelial bladder cancer in cohort 1 of the Phase III THOR trial?
  - a. No significant improvement in progression-free survival (PFS) or overall survival (OS)
  - b. Significant improvement in PFS only
  - c. Significant improvements in PFS and OS
2. The ongoing Phase III SunRISe-5 trial is investigating TAR-200 versus intravesical chemotherapy in which of the following settings?
  - a. First-line therapy for muscle-invasive bladder cancer (MIBC)
  - b. In combination with BCG for high-risk, recurrent non-muscle-invasive bladder cancer (NMIBC)
  - c. After BCG for high-risk, recurrent NMIBC
3. Which of the following descriptions best reflects TAR-210?
  - a. Intravesical gemcitabine/docetaxel
  - b. Intravesical erdafitinib
  - c. Intravesical avelumab
  - d. Systemic mitomycin C
4. Which of the following descriptions best reflects the design of the Alliance A032103 (MODERN) trial for patients with MIBC?
  - a. Adjuvant nivolumab with escalation to nivolumab and relatlimab for patients who remain with detectable circulating tumor DNA (ctDNA)
  - b. Adjuvant nivolumab with de-escalation to surveillance for patients who remain without detectable ctDNA
  - c. Nivolumab and relatlimab for all patients regardless of ctDNA status
  - d. Adjuvant nivolumab with escalation to nivolumab and relatlimab for patients who remain with detectable ctDNA and de-escalation to surveillance for patients who remain without detectable ctDNA
5. Which of the following descriptions best reflects outcomes with neoadjuvant durvalumab and gemcitabine/cisplatin followed by radical cystectomy and adjuvant durvalumab compared to neoadjuvant gemcitabine/cisplatin followed by radical cystectomy alone for patients with MIBC in the Phase III NIAGARA trial?
  - a. No significant improvement in event-free survival (EFS) or OS
  - b. Significant improvement in EFS only
  - c. Significant improvements in EFS and OS